India-Based CRO SIRO ClinPharm Allies with Regulatory Consultancy Firm CamReg

India-based CRO SIRO Clinpharm formed a strategic alliance with Cambridge Regulatory Services, a full-service regulatory consultancy for the pharmaceutical industry. The companies claim their...

Ambrx and Wyeth Sign Multitarget Alliance to Develop Protein Drugs

Deal will exploit Ambrx’ biologics optimization technologies, ReCODE™ and EuCODE™. They enable site-selective substitution of novel amino acids.

Wellcome Trust and Merck Set Up JV to Focus on Vaccines...

India-based Hilleman Laboratories is considering developing vaccines that do not require refrigeration and a vaccine against Group A streptococci.

PerkinElmer Buys GE’s Catalog Radiochemicals, SPA Reagents, and Cytostar-T Plate Assets

Deal pad GPCR and kinase research product lines as well as offerings for detection and screening of new drugs, radiolabeling, bead-based assays, HTS, and reagents.

PPD Opens Lab in Singapore to Support Demand in Southeast Asia

CRO continues making inroads into Asia as well as Central and Eastern Europe. It previously acquired AbCRO and Magen, established an office in Tokyo.

FDA Okays Vaccines for 2009 H1N1 Influenza Virus

CSL, MedImmune, Novartis, and Sanofi Pasteur will begin supply within the next four weeks. Sanofi's vaccine is indicated for children as young as six months.

Value of Elan’s Deal with J&J Drops by 7.6%

Breach of contract with Biogen Idec related to Tysabri forced Elan to eliminate certain financing terms.

NIH to Use Biobase Databases and Analysis Systems for Five More...

NIH has renewed its licensing agreement with Biobase for another five years. The contract provides all 27 NIH institutions with locally installed access to...

Global Pharmaceutical Services Partners with Abridge to Expand Services in India

Global Pharmaceutical Services (GPSI) inked an exclusive partnership with Abridge Clinical Research, an R&D firm located in Mumbai. The arrangement offers services that include...

FDA Lifts Hold on Dynavax’ Phase III HBV Vaccine

Agency is allowing testing in renal-failure patients but not healthy people. Firm would also like to test in people over 40.